Estimado(a) Dr.(a) le invitamos a ver la siguiente cápsula “¿En qué pacientes con Diabetes Tipo 2 es recomendable el uso de insulina degludec para optimizar su control glucémico?”
Por el Dr. José Antonio Cetina Canto. Medicina Interna – Endocrinología. Hospital Star Médica Mérida. Hospital Faro del Mayab (Christus Muguerza). Cédula 6544808.
Referencias
- American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45(Supplement_1):S125–S143.
- Drab SR, Philis-Tsimikas A. A new option for glycemic control: insulin degludec, a new-generation basal insulin with an ultralong duration of action. Pharmacotherapy. 2014 Mar;34(3):291-302.
- Johanssen I, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012 Aug;29(8):2104-14.
- Heise T, et al. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol. 2015;11(8):1193-201.
- Heise T, et al. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. J Diabetes. 2016 Jan;8(1):132-8.
- Heise T, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012 Sep;14(9):859-64.
- American Association of Clinical Endocrinology. Comprehensive type 2 diabetes management algorithm. 2020. https://pro.aace.com/pdfs/diabetes/AACE_2019_Diabetes_Algorithm_03.2021.pdf
Material desarrollado con fines de educación médica continua.
Material exclusivo para profesionales de la salud.
La información aquí presentada es opinión del ponente.
Código interno de aprobación: MX22XUM00023.
